Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
基本信息
- 批准号:6927656
- 负责人:
- 金额:$ 21.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Cardiac arrhythmia is the leading cause of sudden death, particularly, for patients with heart failure. Disappointingly, most current treatments have little or no survival benefits and new therapies are urgently needed. The cardiac calcium release channel (ryanodine receptor type 2, RyR2) is quickly emerging as an important point in the pathogenesis of cardiac arrhythmia. Mutations in RyR2 have been linked to at least 2 forms of cardiac arrhythmias, catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Defective RyR2 channel function has also been implicated in drug-induced cardiac arrhythmia. Our goal is to define the actions of disease-causing RyR2 mutations and of RyR2-interacting pro- and anti-arrhythmic agents, and the molecular mechanism of channel function that mediates their actions, thereby providing the knowledge basis necessary for the development of effective anti-arrhythmic therapies. 3 specific aims are proposed. 1. Define the functional consequences of CPVT RyR2 mutations. The functional impacts of CPVT mutations on RyR2 channel function will be investigated at the whole cell, molecular and single channel levels. 2. Understand the molecular actions of RyR2-interacting pro- and anti-arrhythmic agents. The impacts of RyR2-interacting pro- and anti-arrhythmic agents on RyR2 channel function will be assessed by a combination of techniques including single cell calcium imaging, single channel analysis and radioligand binding. 3. Define the molecular basis of calcium regulation of the RyR2 channel. Site-directed mutagenesis in conjunction with single channel analysis will be employed to systematically define the role of the channel pore region in calcium activation of the RyR2 channel. These studies will shed novel and important insight into the causal mechanisms of RyR2-associated cardiac arrhythmias and sudden death, and will have profound implications to the treatment of cardiac arrhythmias arising from various cardiac diseases including heart failure.
描述(申请人提供):心律失常是猝死的主要原因,尤其是对于心力衰竭患者。令人遗憾的是,目前大多数治疗方法几乎没有生存益处,迫切需要新的治疗方法。心脏钙释放通道(Ryanodine receptor type 2,RyR2)是心律失常发病机制中的一个重要环节。RyR2的突变与至少2种心律失常有关,即儿茶酚胺能多态性室性心动过速(CPVT)和致心律失常性右心室心肌病2型(ARVD 2)。RyR2通道功能缺陷也与药物诱导的心律失常有关。我们的目标是定义致病RyR2突变和RyR2相互作用的促和抗血小板生成剂的作用,以及介导其作用的通道功能的分子机制,从而为开发有效的抗血小板生成疗法提供必要的知识基础。提出了三个具体目标。1.定义CPVT RyR2突变的功能后果。将在全细胞、分子和单通道水平上研究CPVT突变对RyR 2通道功能的功能影响。2.了解RyR2相互作用的促和抗肿瘤剂的分子作用。将通过包括单细胞钙成像、单通道分析和放射性配体结合在内的技术组合来评估RyR2相互作用的促和抗血小板生成剂对RyR2通道功能的影响。3.定义钙调节RyR2通道的分子基础。将采用定点诱变结合单通道分析来系统地确定通道孔区域在RyR2通道的钙激活中的作用。这些研究将为RyR2相关心律失常和猝死的因果机制提供新的重要见解,并将对各种心脏疾病(包括心力衰竭)引起的心律失常的治疗产生深远的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUI RONG WAYNE CHEN其他文献
SUI RONG WAYNE CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUI RONG WAYNE CHEN', 18)}}的其他基金
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
- 批准号:
7918945 - 财政年份:2009
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
- 批准号:
8467016 - 财政年份:2009
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
- 批准号:
7649038 - 财政年份:2009
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
- 批准号:
8116555 - 财政年份:2009
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis and Treatment of Cardiac Arrhythmias
心律失常的分子基础和治疗
- 批准号:
8317617 - 财政年份:2009
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
- 批准号:
7264633 - 财政年份:2005
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
- 批准号:
7484210 - 财政年份:2005
- 资助金额:
$ 21.6万 - 项目类别:
Molecular Basis of Cardiac Arrhythmia and Sudden Death
心律失常和猝死的分子基础
- 批准号:
7080469 - 财政年份:2005
- 资助金额:
$ 21.6万 - 项目类别:
相似海外基金
The Role of Ethnic Racial Discrimination on the Development of Anxious Hypervigilance in Latina Youth
民族种族歧视对拉丁裔青少年焦虑过度警觉的影响
- 批准号:
10752122 - 财政年份:2024
- 资助金额:
$ 21.6万 - 项目类别:
DEVELOPING A HUMAN STEM CELL-DERIVED HEART MODEL TO CHARACTERIZE A NOVEL ARRHYTHMIA SYNDROME
开发人类干细胞衍生的心脏模型来表征新型心律失常综合征
- 批准号:
495592 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Preliminary Study to Establish Heavy Ion Ablation Therapy for Lethal Ventricular Arrhythmia
重离子消融治疗致死性室性心律失常的初步研究
- 批准号:
23K14885 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Optimization of electromechanical monitoring of engineered heart tissues
工程心脏组织机电监测的优化
- 批准号:
10673513 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Spatiotemporal visualization of adenylyl cyclase signaling
腺苷酸环化酶信号传导的时空可视化
- 批准号:
10664707 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Potassium channels and uteroplacental vessels function in pregnant long QT type 1 women
怀孕长 QT 1 型女性的钾通道和子宫胎盘血管功能
- 批准号:
10665263 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Differences in Women and Men with Atrial Fibrillation
女性和男性房颤患者的差异
- 批准号:
10822952 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
3D Bioprinting of a Bioelectric Cell Bridge for Re-engineering Cardiac Conduction
用于重新设计心脏传导的生物电细胞桥的 3D 生物打印
- 批准号:
10753836 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Developing Explainable AI for Equitable Risk Stratification of Atrial Fibrillation and Stroke
开发可解释的人工智能以实现心房颤动和中风的公平风险分层
- 批准号:
10752585 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Personalized Risk Prediction for Prevention and Early Detection of Postoperative Failure to Rescue
个性化风险预测,预防和早期发现术后抢救失败
- 批准号:
10753822 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别: